Our future

[anonymous]

Horizon, Genentech, AbbVie, and Neurocrine rank as top pharma places to work in annual poll!
#neurocrineproud

 

[anonymous]

Horizon, Genentech, AbbVie, and Neurocrine rank as top pharma places to work in annual poll!
#neurocrineproud[/QUOTE

Simply the best, better than all the rest

 

[anonymous]

A few thoughts
Good companies don't need to convince people how good they are.
People leave good companies all the time. Bad management and bad managers cause good people to to leave, or never join in the first place.
Good products sell themselves.

 

[anonymous]

Maybe this is why investigators are calling. They are asking about all of the off label
Promotions and the lies that have been told to the investors.

 

[anonymous]

Beware your management brought down Avanir and they’re bringing down NEUROCRINE !!!!

and they will bring you down with them
They sold Otsuka a bag of goods with all of their lies !!!!

 

[anonymous]

Beware your management brought down Avanir and they’re bringing down NEUROCRINE !!!!

and they will bring you down with them
They sold Otsuka a bag of goods with all of their lies !!!!

 

[anonymous]

Maybe this is why investigators are calling. They are asking about all of the off label
Promotions and the lies that have been told to the investors.

 

[anonymous]

What am I missing? Teva was approved for HD in Aug 2017. Orphan status gives them seven years of exclusive rights to the marketplace, so no competition can launch before Aug 2024 - right?

 

[anonymous]

What am I missing? Teva was approved for HD in Aug 2017. Orphan status gives them seven years of exclusive rights to the marketplace, so no competition can launch before Aug 2024 - right?

You have no idea what you are talking about. Teva launched in April of 2017 for HD. They had the first VMAT-2 on the market.

 

[anonymous]

Yer off by a decade in the US and half a century elsewhere!

Roche had trabenazine in 1950!

Aug 2008 Xenazine (tetrabenazine) FDA approved, but it had been approved for chorea in the UK 1971!

 

[anonymous]

Yer off by a decade in the US and half a century elsewhere!

Roche had trabenazine in 1950!

Aug 2008 Xenazine (tetrabenazine) FDA approved, but it had been approved for chorea in the UK 1971!

Rep Katie Porter to Abvie CEO Richard Gonzales "You lie to patients when you charge them twice as much for an unimproved drug, when you tell us that R&D justifies those price increases."
Isn't the multiple charged for tweaked tetrabenazine 10-time that of tetrabenazine?

 

[anonymous]

Rep Katie Porter to Abvie CEO Richard Gonzales "You lie to patients when you charge them twice as much for an unimproved drug, when you tell us that R&D justifies those price increases."
Isn't the multiple charged for tweaked tetrabenazine 10-time that of tetrabenazine?

Again, you are clueless. tweaked Tetrabenazine in this case totally changed the pharmacokinetics of the drug. So much so that it really isn't the same drug at all. different dosing, different side effect profile, among a few.

 

[anonymous]

Damning assessment of the cost-benefit of vesicular monoamine transporter-2 (VMAT2) inhibitors. ICER report calls for 90% price drop on tardive dyskinesia drugs

 

[anonymous]

Maybe this is why investigators are calling. They are asking about all of the off label
Promotions and the lies that have been told to the investors.

 

[anonymous]

Daily lies that are told to the doctors.

 

[anonymous]

What do you say to critics who claim the higher rates of TD in black men was caused by systemic racial discrimination - black males receive higher doses of neuroleptic drugs primarily through depot medications - and the high cost of VMAT2 inhibitors is further victimization?

 

[anonymous]

What do you say to critics who claim the higher rates of TD in black men was caused by systemic racial discrimination - black males receive higher doses of neuroleptic drugs primarily through depot medications - and the high cost of VMAT2 inhibitors is further victimization?

I say who cares?

 

[anonymous]

New Documentary

Medical Racism: The New Apartheid

 

[anonymous]

Damning assessment of the cost-benefit of vesicular monoamine transporter-2 (VMAT2) inhibitors. ICER report calls for 90% price drop on tardive dyskinesia drugs

Maybe we can hold a 72 hour symposium online, you know, like Lindell's

 

[anonymous]

Who is taking over for Goman?

What got us here isn't what's needed to move forward.